Back to School: How biopharma can reboot drug development. Access exclusive analysis here
FibroGen Inc. (San Francisco, Calif.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to develop and commercialize FibroGen's anemia
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury